₹0 L
Revenue FY25
~₹55 Crore
0%
Revenue CAGR
FY23–FY25
0+
Divisions
Diversified Platform
0 States
Pan-India Presence
South India & East
0+
Products
Across Divisions
What We Do

A Diversified Healthcare Platform

Four focused divisions delivering targeted pharmaceutical and healthcare solutions across India

Division 01
General Pharmaceuticals
Comprehensive portfolio of branded generics across key therapeutic areas including cardiology, diabetology, and general medicine. Marketed under the Accredo umbrella with a strong South India field force.
6 States
Division 02
GynoCare
Launched Nov 2024 — India's next-generation women's health & fertility division. Products developed in consultation with leading IVF specialists and gynaecologists for clinical relevance and superior efficacy.
Launched 2024
Division 03
DiaBeat Care
Cardio-diabetic speciality division with 7 targeted formulations addressing the growing burden of lifestyle diseases. Science-backed Ayurvedic therapeutics for holistic patient care.
7 Formulations
Division 04
In-Vitro Diagnostics
Precision diagnostics portfolio enabling accurate disease detection and monitoring. Addressing the critical last-mile diagnostics gap across South India and East India markets.
Diagnostics

A Decade of Consistent Growth

From ₹28.9 Crore in FY23 to ₹55.5 Crore in FY25 — Accredo has demonstrated exceptional revenue momentum with a 2-year CAGR of 38.5%.

38.5% Revenue CAGR (FY23–FY25)


  View Financial Performance
FY23
₹2,891 Lakhs
FY24
₹4,163 Lakhs
FY25
₹5,548 Lakhs
FY26P
₹7,340 Lakhs*

*Projected / Provisional figures

Our Edge

Why Accredo Pharma

Key differentiators that set us apart in India's competitive pharmaceutical landscape

Backward Integration
Fully owned Pondicherry manufacturing facility (Pregio Pharma subsidiary) ensuring quality control, cost efficiency, and regulatory compliance across all product lines.
Specialist-Led R&D
Products developed in consultation with IVF specialists, gynaecologists, and therapeutic experts — ensuring clinical relevance and faster adoption at the prescription level.
Quality Accreditations
WHO GMP-compliant manufacturing, adherence to Schedule M (revised) requirements, and robust quality management systems ensuring product safety and efficacy.
High-Growth Platform
Four distinct divisions targeting high-growth segments — women's health, diagnostics, cardio-diabetics, and branded generics — providing multiple revenue drivers.
Where We Operate

Pan-India Distribution Network

South & East India
🗺️
Tamil Nadu Kerala Karnataka Andhra Pradesh Telangana Odisha

6 States

Active pharmaceutical marketing operations across South & East India

Robust Distribution

Established stockist and distributor network ensuring last-mile product availability

Manufacturing

Pondicherry facility — WHO GMP compliant, Schedule M ready, backward integrated

Expansion Ready

IPO proceeds earmarked for geographic expansion into North & West India markets

What Doctors Say

Trusted by Healthcare Professionals

Physicians across South India trust Accredo's quality, consistency, and clinical expertise.

★★★★★

"Accredo's MR team is highly professional and knowledgeable. Their General Pharma range maintains consistent quality and their supply chain is reliable — something that matters greatly in patient care."

RI
Dr. Ramesh Iyer
MD — General Medicine, Chennai
★★★★★

"I have been prescribing Accredo's GynoCare range for over two years. The formulations are well-researched, patient compliance is excellent, and I always see the desired clinical outcomes."

PS
Dr. Priya Suresh
DGO, MBBS — Obstetrician & Gynaecologist
★★★★★

"The DiaBeat Care division brings focused, specialist-grade molecules for diabetic patients. Their team understands the therapeutic needs deeply, and I appreciate their commitment to clinical education."

VN
Dr. Venkatesh Nair
MBBS, MD — Diabetologist, Bengaluru

🚀 Accredo Pharma — IPO Coming Soon

Be part of India's fastest-growing diversified pharmaceutical platform. BSE SME IPO of approximately ₹40 Crore — your opportunity to invest in a decade of proven growth.

  Investor Relations   About Accredo

Artin Pain Relief Spray

 Rapid Pain Relief

Reduces Inflammation

accelerate recovery

    Cooling & Soothing Effect

    Counter-Irritant Action

    pain management.